EasyM: Blood-based MRD for MM

Heading into #ASCO25 we're happy to share our latest paper with the #myeloma community. Dr. Slade has been instrumental to helping EasyM develop its state-of-the art non-invasive #mmMRD assay and we look forward to the next ! EasyM is a CLIA certified LDT and not FDA approved

Could Reliable Blood Based MRD Testing Make Drug Holidays a Reality? 💡 For many patients with multiple myeloma, treatment never truly stops, even in deep remission. But what if frequent, reliable, and patient-friendly blood MRD testing could change that? By tracking disease…

Beyond MRD: Tracking Therapy and Disease Together As oncology moves toward personalized medicine, clonotypic mass spectrometry (e.g., EasyM) could offer the ability to track both myeloma MRD levels and therapeutic antibody levels in the same blood sample. 💡 Why this matters:…

It was a true privilege for the EasyM team to participate in the @MyelomaCanada Minimal Residual Disease (MRD) Summit. Being part of such a thoughtful and forward looking conversation about the future of MRD testing in Canada was both inspiring and deeply meaningful to our entire…

ASH 2025 is just THREE WEEKS away! The EasyM team is excited to connect, share insights, and talk about all things multiple myeloma. DM us to set up a time to meet. We’d love to connect with you at #ASH25! Looking forward to an inspiring week ahead. #MultipleMyeloma #MMSM #MM…

Not all Multiple Myeloma MRD Mass Spectrometry tests are created equal 💡 You’ve probably heard of SPEP and IFE, but imagine if tests had much better sensitivity and specificity…That’s what mass spectrometry tests offer! While all mass spectrometry tests are a huge step…

ASH 2025 Abstract Highlight 📢 Title: Tracking Peripheral Residual Disease in Myeloma: Clonotypic Sequencing and Mass Spectrometry in the Teclistamab Era A Montreal team (Sabouret et al., Hôpital Maisonneuve-Rosemont) aimed to assess the performance of EasyM and intact mass…

ASH 2025 Abstract Highlight 📣 Title: Sensitive Peripheral Residual Disease Detection Using Clonotypic Mass Spectrometry (EasyM) in Patients with Newly Diagnosed Multiple Myeloma A study led by Sharma et al. at Princess Margaret Cancer Centre (PMCC) is evaluating EasyM, a…

🌟 EasyM Team Spotlight: Jenna Kerry 🌟 We’re thrilled to shine the spotlight on Jenna Kerry, our Program Manager here at EasyM! Jenna plays a central role in keeping our projects and partnerships running smoothly. She oversees the life cycle of key initiatives, from strategic…

🚨 ASH 2025 Abstracts are Live! We’re excited to share EasyM’s latest research in Multiple Myeloma: 📄10587: Tracking Peripheral Residual Disease in Myeloma: Clonotypic Sequencing and Mass Spectrometry in the Teclistamab Era - meetings-api.hematology.org/api/abstract/v… 📄15025: Sensitive…

Current Evidence for MRD Adapted Therapy in Multiple Myeloma 📢 There is no denying that Minimal Residual Disease (MRD) is a strong prognostic factor. The question on everyone’s mind is whether or not it can help guide clinical decision making. Recent clinical trials, including…

Multiple Myeloma Treatment Should be Personalized and MRD could help💡 Dr. Paul Richardson (@DanaFarber) and colleagues highlight the importance of tailoring treatment for newly diagnosed multiple myeloma patients. By evaluating minimal residual disease (MRD), clinicians can…

MRD Negativity Associated with PFS and OS Benefit in DREAMM-8 Multiple Myeloma Trial! MRD negativity predicts better outcomes in relapsed/refractory multiple myeloma. Patients on BPd (belantamab mafodotin + pomalidomide + dexamethasone) had 5–7× higher MRD-negative rates than…

MRD vs No MRD guided treatment for Myeloma: A great debate between Dr. Saad Usmani (@szusmani) and Dr. Luciano Costa (@End_myeloma) Key takeaways from the Plasma Cell Disorders Symposium MRD debate: - MRD results guide post-therapy prognosis discussions in the clinic. - Must be…

2025 Update: MRD-Guided Maintenance in Standard-Risk Myeloma Mayo Clinic’s latest mSMART guidelines now recommend that standard-risk multiple myeloma patients who remain MRD positive post-transplant consider doublet maintenance: lenalidomide + anti-CD38 therapy. Why it matters:…

🌟 EasyM Team Spotlight: Zac McDonald, PhD 🌟 We’re excited to shine the spotlight on Zac, a Senior Scientist at EasyM! Zac plays a key role in advancing our research and development efforts, helping to innovate and refine the science behind MRD testing. His expertise,…

What is Hemodilution? 💡 Hemodilution is a hidden challenge in bone marrow-based MRD Testing for Multiple Myeloma. When bone marrow aspirates are diluted with peripheral blood, the number of plasma cells, and therefore the sensitivity of MRD detection, can drop dramatically.…

MRD isn’t just a research metric 💡 Achieving and sustaining minimal residual disease (MRD) negativity is now a cornerstone goal in multiple myeloma (MM) treatment. A NEW review by Dr. Jennifer Cooperrider and @bdermanmd highlights: - The prognostic power of MRD negativity in…

Our team is at ESMO 2025! 📢 We're looking forward to connecting with innovators, experts, and thought leaders in oncology. Want to meet? DM us to schedule a chat and explore how EasyM is transforming MRD for Multiple Myeloma! #ESMO25 #MultipleMyeloma #MRD #BloodTest #Oncology